To cater to the special situation of much reduced oral bioavailability which occurs in severe @entity2704 attacks with pronounced @entity390 and @entity391 , @entity9251 can also be used in a subcutaneous form that can be self-administered. The aim of this study was to analyze the practicability and acceptance of a method of self-administration ("Glaxo- @entity8907 ") for treatment of severe @entity2704 attacks by subcutaneous injection of @entity9251 . The Glaxo- @entity8907 was compared with the conventional autoinjector for subcutaneous administration of @entity9251 . The multicenter study was conducted under practical conditions by 150 office-based physicians in Germany. @entity1 who commonly suffered from severe @entity2704 attacks were given a careful explanation of how to use the device ("Glaxo- @entity8907 ") for self-administration of subcutaneous @entity9251 and were able to practice using it under guidance. They were given a Glaxo- @entity8907 with two @entity9251 refills to take with them for treating their own @entity2704 attacks. The @entity1 used a @entity10 diary to document administration outside the practice session. A total of 376 @entity1 were included in the study. The major findings were that 80% of the @entity1 rated the Glaxo- @entity8907 "very easy" or "easy" to use, and only 6.4% rated it "difficult" or "very difficult." Compared with the conventional autoinjector, the Glaxo- @entity8907 was rated "much better" or "better" by 77.9% of @entity1 . Only 8.5% considered the Glaxo- @entity8907 "worse" or "much worse" than the conventional autoinjector. The figures show that the great majority of @entity1 found it easy to use @entity9251 for treating severe @entity2704 attacks by self-administration under practical conditions. Thus, especially for @entity1 who suffer from severe @entity390 , @entity391 , or @entity294 during @entity2704 attacks, this method of delivery is an easily used means of arresting @entity2704 attacks.

Practicability and acceptance of subcutaneous self-administration of the selective serotonin agonist XXXX .

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity390 :: ('MESH:D009325', 'Disease') :: ['nausea'] @entity294 :: ('MESH:D003967', 'Disease') :: ['diarrhea'] @entity391 :: ('MESH:D014839', 'Disease') :: ['vomiting'] @entity9251 :: ('MESH:D018170', 'Chemical') :: ['sumatriptan'] @entity2704 :: ('MESH:D008881', 'Disease') :: ['migraine'] @entity8907 :: ('340348', 'Gene') :: ['Pen'] @entity10 :: ('MESH:D006261', 'Disease') :: ['headache']
@entity9251 :: (MESH:D018170,Chemical) :: ['sumatriptan']
